Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPC+Apatinib+Camrelizumab vs GP+Camrelizumab in High-Risk NPC
NCT06438627Phase 3Recruiting
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib, paclitaxel and capecitabine in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoint: Failure-Free Survival at 3 years. Started May 2024; status: recruiting.
02
Drugs
Rivoceranibpaclitaxelcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06438627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438627.